Evaluating only Artera’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Regulation.
Key Events Timeline
FOUNDING
MILESTONE
CRISIS
SHUTDOWN
Full Analysis
Free · no account needed
Documented cause
Artera built AI-powered pathology analysis software that predicts cancer treatment outcomes from tissue images. With $145M raised and a landmark NEJM publication validating its prostate cancer test, the science was compelling. But FDA 510(k) clearance took far longer than projected, and hospital procurement teams required clearance before purchasing at scale. The company burned through capital waiting for regulatory timelines that kept slipping, and had to cut staff significantly in 2024.
Lesson
“Medical AI startups with FDA pathway dependencies must raise de-risking capital rounds timed to regulatory milestones — not generic growth capital that burns before clearance arrives.”